WHAT IS CLAIMED IS:

1. A compound of Formula (I):



(I)

or a stereoisomer or a pharmaceutically acceptable salt form thereof, wherein:

R^1 is selected from

H, $C(=O)R^{2a}$, $C(=O)OR^{2a}$, $S(=O)R^{2a}$, $S(=O)_2R^{2a}$,

C_{3-7} cycloalkyl,

C_{1-4} alkyl substituted with 0-3 R^2,

C_{2-4} alkenyl substituted with 0-2 R^2,

C_{2-4} alkynyl substituted with 0-2 R^2,

aryl substituted with 0-5 R^{42},

C_{3-10} carbocyclic residue substituted with 0-3 R^{41}, and

5-6 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R^{41};

R^2, at each occurrence, is independently selected from

halo, C_{1-3} haloalkyl, C_{1-4} alkoxy, C_{1-4} alkyl,

C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl,

aryl substituted with 0-5 R^{42};

C_{3-10} carbocyclic residue substituted with 0-3 R^{41}, and

5-6 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R^{41};

R^{2a} is H, C_{1-4} alkyl, (aryl)C_{1-4} alkyl-, or
(C_{3-6} cycloalkyl)C_{1-4} alkyl-;

R^{4a} is H or C_{1-4} alkyl;

R^5 is H, C_{1-4} alkyl substituted with 0-2 R^{20},
-C(=O)(C_{1-4} alkyl), -C(=O)O(C_{1-4} alkyl), or C_{1-4} haloalkyl;

R^6 is selected from
halo, $-CF_3$, $-OCF_3$, -CN, $-NO_2$, $-OCH_3$, $-SCH_3$, $-CF_2CF_3$, -O-R^{11},
$-OCF_2CF_3$, $-OCF_2H$, $-OCF_2CH_3$,
-S-R^{11}, -S(=O)-R^{11}, -S(=O)$_2$-R^{11}, -S(=O)-NR^{10}-R^{11},
-S(=O)$_2$-NR^{10}-R^{11}, -NR^{10}-R^{11}, -CH_2O-R^{11}, -CH_2S-R^{11},
CH_2S(=O)-R^{11}, CH_2S(=O) $_2$-R^{11},-CH_2NR^{10}-R^{11}, -C(=O)NR^{10}-R^{11}
C_{1-4} haloalkyl, (C_{1-4} haloalkyl)oxy;
C_{1-4} alkyl substituted with 0-2 R^{20},
C_{2-4} alkenyl substituted with 0-2 R^{20},
C_{2-4} alkynyl substituted with 0-1 R^{20}, and
C_{3-6} carbocyclic residue substituted with 0-3 R^{21},

R^7 and R^9 are independently selected from
H, F, Cl, Br, $-CF_3$, $-OCF_3$, -OH, -CN, $-NO_2$, $-CF_2CF_3$, C_{1-4} alkyl,
C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, and
(C_{1-4} haloalkyl)oxy;

R^8 is selected from

halo, $-CF_3$, $-OCF_3$, -OH, -CN, $-NO_2$, $-OCH_3$, $-SCH_3$, $-CF_2CF_3$,
$-OR^{12}$, $-SR^{12}$, $-NR^{12}R^{13}$, -C(O)H, $-C(O)R^{12}$, $-C(O)NR^{12}R^{13}$,
$-NR^{14}C(O)R^{12}$, $-C(O)OR^{12}$, $-OC(O)R^{12}$, $-OC(O)OR^{12}$,
$-S(O)R^{12}$, $-S(O)_2R^{12}$, $-S(O)NR^{12}R^{13}$, $-S(O)_2NR^{12}R^{13}$,
$-NR^{14}S(O)R^{12}$, $-NR^{14}S(O)_2R^{12}$, $-NR^{12}C(O)R^{15}$, $-NR^{12}C(O)OR^{15}$,
$-NR^{12}S(O)_2R^{15}$, $-NR^{12}C(O)NHR^{15}$;
$C_{1\text{-}6}$ alkyl substituted with 0-2 R^{8a},
$C_{2\text{-}6}$ alkenyl substituted with 0-2 R^{8a},
$C_{2\text{-}6}$ alkynyl substituted with 0-2 R^{8a},
$C_{3\text{-}6}$ cycloalkyl substituted with 0-2 R^{8a},
$C_{3\text{-}10}$ carbocyclic residue substituted with 0-3 R^{33};

R^{8a}, at each occurrence, is independently selected from

halo, $-CF_3$, $-OCF_3$, -OH, -CN, $-NO_2$, $-CF_2CF_3$,
methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl,
$-OR^{12}$, $-SR^{12}$, $-NR^{12}R^{13}$, -C(O)H, $-C(O)R^{12}$, $-C(O)NR^{12}R^{13}$,
$-NR^{14}C(O)R^{12}$, $-C(O)OR^{12}$, $-OC(O)R^{12}$, $-OC(O)OR^{12}$,
$-S(O)R^{12}$, $-S(O)_2R^{12}$, $-S(O)NR^{12}R^{13}$, $-S(O)_2NR^{12}R^{13}$,
$-NR^{14}S(O)R^{12}$, $-NR^{14}S(O)_2R^{12}$, $-NR^{12}C(O)R^{15}$, $-NR^{12}C(O)OR^{15}$,
$-NR^{12}S(O)_2R^{15}$, $-NR^{12}C(O)NHR^{15}$;
phenyl substituted with 0-5 R^{33};
$C_{3\text{-}10}$ carbocyclic residue substituted with 0-3 R^{33}, and
5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R^{33};

R^{10} is H or $C_{1\text{-}4}$ alkyl;

R^{11} is selected from

C_{1-6} alkyl substituted with 0-2 R^{20},

C_{2-6} alkenyl substituted with 0-2 R^{20},

C_{2-6} alkynyl substituted with 0-1 R^{20},

C_{3-10} carbocyclic residue substituted with 0-3 R^{21},

aryl substituted with 0-5 R^{23}, and

5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R^{21};

alternatively, R^{10} and R^{11} join to form a 5- or 6-membered ring optionally substituted with -O- or -N(R^{14})-;

alternatively, R^{10} and R^{11} when attached to N may be combined to form a 9- or 10-membered bicyclic heterocyclic ring system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S, wherein said bicyclic heterocyclic ring system is unsaturated or partially saturated, wherein said bicyclic heterocyclic ring system is substituted with 0-3 R^{16};

R^{12} is selected from H,

C_{1-6} alkyl substituted with 0-2 R^{12a},

C_{2-6} alkenyl substituted with 0-2 R^{12a},

C_{2-6} alkynyl substituted with 0-2 R^{12a},

C_{3-6} cycloalkyl substituted with 0-3 R^{33},

aryl substituted with 0-5 R^{33};

C_{3-10} carbocyclic residue substituted with 0-3 R^{33}, and

5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R^{33};

R^{12a}, at each occurrence, is independently selected from

H, halo, -OH, -CN, $-NO_2$, $-CO_2H$, $-SO_2R^{45}$, $-SOR^{45}$, $-SR^{45}$, $-NR^{46}SO_2R^{45}$, $-NR^{46}COR^{45}$, $-NR^{46}R^{47}$, $-SO_2NR^{46}R^{47}$, $-CONR^{46}R^{47}$, $-OR^{45}$, =O,

C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl,

phenyl substituted with 0-5 R^{33};

C_{3-10} carbocyclic residue substituted with 0-3 R^{33}, and

5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R^{33};

R^{13}, at each occurrence, is independently selected from

H, C_{1-4} alkyl, C_{2-4} alkenyl, and C_{2-4} alkynyl;

alternatively, R^{12} and R^{13} join to form a 5- or 6-membered ring optionally substituted with -O- or $-N(R^{14})-$;

alternatively, R^{12} and R^{13} when attached to N may be combined to form a 9- or 10-membered bicyclic heterocyclic ring system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S, wherein said bicyclic heterocyclic ring system is unsaturated or partially saturated, wherein said bicyclic heterocyclic ring system is substituted with 0-3 R^{16};

R^{14}, at each occurrence, is independently selected from H and C_{1-4} alkyl;

R^{15}, at each occurrence, is independently selected from

H, C_{1-4} alkyl, C_{2-4} alkenyl, and C_{2-4} alkynyl;

R^{16}, at each occurrence, is independently selected from

H, OH, halo, CN, NO_2, CF_3, SO_2R^{45}, $NR^{46}R^{47}$, -C(=O)H,

C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkyl,

C_{1-3} haloalkyl-oxy-, and C_{1-3} alkyloxy-;

R^{20} is selected from

H, halo, -OH, $-CF_3$, -CN, $-NO_2$, $-CO_2H$, $-SO_2R^{45}$,

$-SOR^{45}$, $-SR^{45}$, $-NR^{46}SO_2R^{45}$, $-NR^{46}COR^{45}$, $-NR^{46}R^{47}$,

C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-4} alkoxy,

C_{1-4} haloalkyl;

C_{3-10} carbocyclic residue substituted with 0-3 R^{21};

aryl substituted with 0-5 R^{23}; and

5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R^{21};

R^{21}, at each occurrence, is independently selected from

H, OH, halo, CF_3, SO_2R^{45}, $NR^{46}R^{47}$, CN, NO_2, =O, C_{1-4} alkyl,

C_{1-4} alkoxy, and (C_{1-4} haloalkyl)oxy;

R^{23}, at each occurrence, is independently selected from

H, OH, halo, CF_3, SO_2R^{45}, $NR^{46}R^{47}$, CN, NO_2, C_{1-4} alkyl,

C_{1-4} alkoxy, and (C_{1-4} haloalkyl)oxy;

R^{33}, at each occurrence, is independently selected from

H, OH, halo, -CN, $-NO_2$, $-CF_3$, $-OCF_3$, $-SO_2R^{35}$, $-S(=O)R^{35}$, $-SR^{35}$,

$-NR^{36}R^{37}$, $-NHC(=O)R^{35}$, $-C(=O)NR^{36}R^{37}$, -C(=O)H, $-C(=O)R^{35}$,

$-C(=O)OR^{35}$, $-OC(=O)R^{35}$, $-OR^{35}$,
C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-4} haloalkyl,
C_{1-4} alkoxy, (C_{1-4} haloalkyl)oxy,
C_{3-6} cycloalkyl, phenyl, aryl substituted with 0-2 R^{34},
C_{1-6} alkyl substituted with R^{34}, and
C_{2-6} alkenyl substituted with R^{34};

R^{34}, at each occurrence, is independently selected from
OH, C_{1-4} alkoxy, $-SO_2R^{35}$, $-NR^{36}R^{37}$, $NR^{36}R^{37}C(=O)-$, and
(C_{1-4} alkyl)CO_2-;

R^{35}, at each occurrence, is independently selected from
C_{1-4} alkyl, C_{1-4} haloalkyl, C_{3-6} cycloalkyl,
(C_{3-6} cycloalkyl)methyl-, and (C_{3-6} cycloalkyl)ethyl-;

R^{36}, at each occurrence, is independently selected from H and C_{1-4} alkyl;

R^{37}, at each occurrence, is independently selected from H, C_{1-4} alkyl,
$-C(=O)NH(C_{1-4}$ alkyl), $-SO_2(C_{1-4}$ alkyl),
$-C(=O)O(C_{1-4}$ alkyl), $-C(=O)(C_{1-4}$ alkyl), and -C(=O)H;

R^{41}, at each occurrence, is independently selected from
H, CF_3, halo, OH, CO_2H, SO_2R^{45}, $NR^{46}R^{47}$, NO_2, CN, =O,
C_{1-4} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-4} alkoxy, and C_{1-4} haloalkyl;

R^{42}, at each occurrence, is independently selected from
H, CF_3, halo, OH, CO_2H, SO_2R^{45}, SOR^{45}, SR^{45}, $NR^{46}SO_2R^{45}$,
$NR^{46}COR^{45}$, $NR^{46}R^{47}$, NO_2, CN,
C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-4} alkoxy, and C_{1-4} haloalkyl;

R^{45} is C_{1-4} alkyl;

R^{46}, at each occurrence, is independently selected from H and C_{1-4} alkyl;

R^{47}, at each occurrence, is independently selected from H, C_{1-4} alkyl, -C(=O)NH(C_{1-4} alkyl), -SO_2(C_{1-4} alkyl), -C(=O)O(C_{1-4} alkyl), -C(=O)(C_{1-4} alkyl), and -C(=O)H;

m is 1 or 2;

provided that when R^{11} is C_{1-6} alkyl, then R^1 is not a C_{1-4} alkyl substituted by a) an unsubstituted 3H-pyrimidine-4-one moiety, b) a substituted 3H-pyrimidine-4-one moiety, c) an unsubstituted bicyclic derivative of 3H-pyrimidine-4-one, or d) a substituted bicyclic derivative of 3H-pyrimidine-4-one;

provided that when R^6 is -O-R^{11} and R^6 is C_{1-6} alkyl; then R^{8a} is not a substituted or unsubstituted indole moiety.

2. A compound of Claim 1 of Formula (Ia):



(Ia)

or a stereoisomer or a pharmaceutically acceptable salt form thereof, wherein:

R^1 is selected from

H, C_{1-3} haloalkyl, C_{3-6} cycloalkyl,

C_{1-4} alkyl substituted with 0-2 R^2,

C_{2-4} alkenyl substituted with 0-2 R^2, and

C_{2-4} alkynyl substituted with 0-2 R^2;

R^2, at each occurrence, is independently selected from

halo, C_{1-3} haloalkyl, C_{1-4} alkoxy, C_{1-4} alkyl,

C_{3-6} cycloalkyl, and phenyl substituted with 0-5 R^{42};

R^{4a} is H or C_{1-4} alkyl;

R^5 is H, C_{1-4} alkyl substituted with 0-1 R^{20}, or C_{1-4} haloalkyl;

R^6 is selected from

halo, $-CF_3$, $-OCF_3$, -CN, $-NO_2$, $-OCH_3$, $-SCH_3$, $-CF_2CF_3$, $-O-R^{11}$,

$-OCF_2CF_3$, $-OCF_2H$, $-OCF_2CH_3$,

$-S-R^{11}$, $-S(=O)-R^{11}$, $-S(=O)_2-R^{11}$, $-NR^{10}-R^{11}$, $-CH_2O-R^{11}$,

$-CH_2S-R^{11}$, $CH_2S(=O)-R^{11}$, $CH_2S(=O)_2-R^{11}$, $-CH_2NR^{10}-R^{11}$,

C_{1-4} haloalkyl, (C_{1-4} haloalkyl)oxy;

C_{1-4} alkyl substituted with 0-2 R^{20},

C_{2-4} alkenyl substituted with 0-2 R^{20},

C_{2-4} alkynyl substituted with 0-1 R^{20}, and

C_{3-6} carbocyclic residue substituted with 0-3 R^{21},

R^7 and R^9 are independently selected from

H, F, Cl, Br, $-CF_3$, $-OCF_3$, -OH, -CN, $-NO_2$, CF_2CF_3,C_{1-4} alkyl,

C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, and

(C_{1-4} haloalkyl)oxy;

R^8 is selected from

halo, $-CF_3$, $-OCF_3$, -OH, -CN, $-NO_2$, $-OCH_3$, $-SCH_3$, $-CF_2CF_3$,

$-OR^{12}$, $-SR^{12}$, $-NR^{12}R^{13}$, -C(O)H, $-C(O)R^{12}$, $-C(O)NR^{12}R^{13}$,

$-NR^{14}C(O)R^{12}$, $-C(O)OR^{12}$, $-OC(O)R^{12}$, $-OC(O)OR^{12}$,

$-S(O)R^{12}$, $-S(O)_2R^{12}$, $-S(O)NR^{12}R^{13}$, $-S(O)_2NR^{12}R^{13}$,

$-NR^{14}S(O)R^{12}$, $-NR^{14}S(O)_2R^{12}$, $-NR^{12}C(O)R^{15}$, $-NR^{12}C(O)OR^{15}$,

$-NR^{12}S(O)_2R^{15}$, $-NR^{12}C(O)NHR^{15}$;

C_{1-6} alkyl substituted with 0-2 R^{8a},

C_{2-6} alkenyl substituted with 0-2 R^{8a},

C_{2-6} alkynyl substituted with 0-2 R^{8a},

C_{3-6} cycloalkyl substituted with 0-2 R^{8a}, and

C_{3-10} carbocyclic residue substituted with 0-3 R^{33};

R^{8a}, at each occurrence, is independently selected from

halo, $-CF_3$, $-OCF_3$, -OH, -CN, $-NO_2$, $-CF_2CF_3$,

methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl,

$-OR^{12}$, $-SR^{12}$, $-NR^{12}R^{13}$, -C(O)H, $-C(O)R^{12}$, $-C(O)NR^{12}R^{13}$,

$-NR^{14}C(O)R^{12}$, $-C(O)OR^{12}$, $-OC(O)R^{12}$, $-OC(O)OR^{12}$,

$-S(O)R^{12}$, $-S(O)_2R^{12}$, $-S(O)NR^{12}R^{13}$, $-S(O)_2NR^{12}R^{13}$,

$-NR^{14}S(O)R^{12}$, $-NR^{14}S(O)_2R^{12}$, $-NR^{12}C(O)R^{15}$, $-NR^{12}C(O)OR^{15}$,

$-NR^{12}S(O)_2R^{15}$, $-NR^{12}C(O)NHR^{15}$;

phenyl substituted with 0-5 R^{33};

C_{3-10} carbocyclic residue substituted with 0-3 R^{33}, and

5-6 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R^{33};

R^{10} is H or C_{1-4} alkyl;

R^{11} is selected from

C_{1-6} alkyl substituted with 0-2 R^{20},

C_{2-6} alkenyl substituted with 0-2 R^{20},

C_{2-6} alkynyl substituted with 0-1 R^{20},

C_{3-10} carbocyclic residue substituted with 0-3 R^{21},

aryl substituted with 0-5 R^{23}, and

5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R^{21};

alternatively, R^{10} and R^{11} join to form a 5- or 6-membered ring optionally substituted with -O- or -N(R^{14})-;

alternatively, R^{10} and R^{11} when attached to N may be combined to form a 9- or 10-membered bicyclic heterocyclic ring system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S, wherein said bicyclic heterocyclic ring system is unsaturated or partially saturated, wherein said bicyclic heterocyclic ring system is substituted with 0-3 R^{16};

R^{12} is selected from H,

C_{1-6} alkyl substituted with 0-2 R^{12a},

C_{2-6} alkenyl substituted with 0-2 R^{12a},

C_{2-6} alkynyl substituted with 0-2 R^{12a},

C_{3-6} cycloalkyl substituted with 0-3 R^{33},

aryl substituted with 0-5 R^{33};

C_{3-10} carbocyclic residue substituted with 0-3 R^{33}, and

5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R^{33};

R^{12a}, at each occurrence, is independently selected from

H, halo, -OH, -CN, $-NO_2$, $-CO_2H$, $-SO_2R^{45}$, $-SOR^{45}$, $-SR^{45}$, $-NR^{46}SO_2R^{45}$, $-NR^{46}COR^{45}$, $-NR^{46}R^{47}$, $-SO_2NR^{46}R^{47}$, $-CONR^{46}R^{47}$, $-OR^{45}$, =O,

C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl,

phenyl substituted with 0-5 R^{33};

C_{3-10} carbocyclic residue substituted with 0-3 R^{33}, and

5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R^{33};

R^{13}, at each occurrence, is independently selected from

H, C_{1-4} alkyl, C_{2-4} alkenyl, and C_{2-4} alkynyl;

alternatively, R^{12} and R^{13} join to form a 5- or 6-membered ring optionally substituted with -O- or $-N(R^{14})-$;

alternatively, R^{12} and R^{13} when attached to N may be combined to form a 9- or 10-membered bicyclic heterocyclic ring system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S, wherein said bicyclic heterocyclic ring system is unsaturated or partially saturated, wherein said bicyclic heterocyclic ring system is substituted with 0-3 R^{16};

R^{14}, at each occurrence, is independently selected from H and C_{1-4} alkyl;

R^{15}, at each occurrence, is independently selected from

H, C_{1-4} alkyl, C_{2-4} alkenyl, and C_{2-4} alkynyl;

R^{16}, at each occurrence, is independently selected from

H, OH, halo, CN, NO_2, CF_3, SO_2R^{45}, $NR^{46}R^{47}$, -C(=O)H,

C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkyl,

C_{1-3} haloalkyl-oxy-, and C_{1-3} alkyloxy-;

R^{20} is selected from

H, halo, -OH, $-CF_3$, -CN, $-NO_2$, $-CO_2H$, $-SO_2R^{45}$,

$-SOR^{45}$, $-SR^{45}$, $-NR^{46}SO_2R^{45}$, $-NR^{46}COR^{45}$, $-NR^{46}R^{47}$,

C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-4} alkoxy,

C_{1-4} haloalkyl;

C_{3-10} carbocyclic residue substituted with 0-3 R^{21};

aryl substituted with 0-5 R^{23}; and

5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R^{21};

R^{21}, at each occurrence, is independently selected from

H, OH, halo, CF_3, SO_2R^{45}, $NR^{46}R^{47}$, CN, NO_2, =O, C_{1-4} alkyl;

C_{1-4} alkoxy, and (C_{1-4} haloalkyl)oxy;

R^{23}, at each occurrence, is independently selected from

H, OH, halo, CF_3, SO_2R^{45}, $NR^{46}R^{47}$, CN, NO_2, C_{1-4} alkyl;

C_{1-4} alkoxy, and (C_{1-4} haloalkyl)oxy;

R^{33}, at each occurrence, is independently selected from

H, OH, halo, -CN, $-NO_2$, $-CF_3$, $-OCF_3$, $-SO_2R^{35}$, $-S(=O)R^{35}$,

$-SR^{35}$, $-NR^{36}R^{37}$, $-NHC(=O)R^{35}$, $-C(=O)NR^{36}R^{37}$,

-C(=O)H, -C(=O)R^{35}, -C(=O)OR^{35}, -OC(=O)R^{35}, -OR^{35},
C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-4} haloalkyl,
C_{1-4} alkoxy, (C_{1-4} haloalkyl)oxy,
C_{3-6} cycloalkyl, phenyl, aryl substituted with 0-2 R^{34},
C_{1-6} alkyl substituted with R^{34}, and
C_{2-6} alkenyl substituted with R^{34};

R^{34}, at each occurrence, is independently selected from
OH, C_{1-4} alkoxy, -SO_2R^{35}, -$NR^{36}R^{37}$, $NR^{36}R^{37}C(=O)$-, and
(C_{1-4} alkyl)CO_2-;

R^{35}, at each occurrence, is independently selected from
C_{1-4} alkyl, C_{1-4} haloalkyl, C_{3-6} cycloalkyl,
(C_{3-6} cycloalkyl)methyl-, and (C_{3-6} cycloalkyl)ethyl-;

R^{36}, at each occurrence, is independently selected from H and C_{1-4} alkyl;

R^{37}, at each occurrence, is independently selected from H, C_{1-4} alkyl,
-C(=O)NH(C_{1-4} alkyl), -SO_2(C_{1-4} alkyl),
-C(=O)O(C_{1-4} alkyl), -C(=O)(C_{1-4} alkyl), and -C(=O)H;

R^{41}, at each occurrence, is independently selected from
H, CF_3, halo, OH, CO_2H, SO_2R^{45}, $NR^{46}R^{47}$, NO_2, CN, =O,
C_{1-4} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, C_{1-4} alkoxy, and C_{1-4} haloalkyl;

R^{42}, at each occurrence, is independently selected from
H, CF_3, halo, OH, CO_2H, SO_2R^{45}, SOR^{45}, SR^{45}, $NR^{46}SO_2R^{45}$,
$NR^{46}COR^{45}$, $NR^{46}R^{47}$, NO_2, CN, C_{1-4} alkyl, C_{2-6} alkenyl,
C_{2-6} alkynyl, C_{1-4} alkoxy, and C_{1-4} haloalkyl;

R^{45} is C_{1-4} alkyl;

R^{46}, at each occurrence, is independently selected from H and C_{1-4} alkyl;

R^{47}, at each occurrence, is independently selected from H, C_{1-4} alkyl,
-C(=O)NH(C_{1-4} alkyl), -SO_2(C_{1-4} alkyl),
-C(=O)O(C_{1-4} alkyl), -C(=O)(C_{1-4} alkyl), and -C(=O)H;

m is 1 or 2.

3. A compound of Claim 2 of Formula (Ia):



(Ia)

or a stereoisomer or a pharmaceutically acceptable salt form thereof, wherein:

R^1 is selected from
H, CF_3, methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
C_{1-4} alkyl substituted with 0-1 R^2,
C_{2-4} alkenyl substituted with 0-1 R^2, and
C_{2-4} alkynyl substituted with 0-1 R^2;

R^2 is selected from

F, Cl, CH_2F, CHF_2, CF_3, methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and phenyl;

R^{4a} is H or methyl;

R^5 is H, methyl, or ethyl;

R^6 is selected from

F, Cl, $-CF_3$, $-OCF_3$, $-CF_2CF_3$, $-OCF_2CF_3$, $-OCF_2H$, $-OCF_2CH_3$, -CN, $-NO_2$, $-O-R^{11}$, $-S-R^{11}$, $-S(=O)-R^{11}$, $-S(=O)_2-R^{11}$, $-CH_2O-R^{11}$, $-CH_2S-R^{11}$, $CH_2S(=O)-R^{11}$, $CH_2S(=O)_2-R^{11}$, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and s-butyl;

R^7 and R^9 are independently selected from

H, F, Cl, $-CH_3$, $-OCH_3$, $-CF_3$, $-OCF_3$, -CN, and $-NO_2$;

R^8 is selected from

$-OR^{12}$, $-SR^{12}$, $-NR^{12}R^{13}$, $-C(O)R^{12}$, $-S(O)R^{12}$, $-S(O)_2R^{12}$,

$C_{1\text{-}6}$ alkyl substituted with 0-2 R^{8a},

$C_{2\text{-}6}$ alkenyl substituted with 0-2 R^{8a},

$C_{2\text{-}6}$ alkynyl substituted with 0-2 R^{8a},

$C_{3\text{-}6}$ cycloalkyl substituted with 0-2 R^{8a}, and

$C_{3\text{-}10}$ carbocyclic residue substituted with 0-3 R^{33};

R^{8a}, at each occurrence, is independently selected from

halo, $-CF_3$, $-OCF_3$, -OH, -CN, $-NO_2$, $-CF_2CF_3$, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, $-OR^{12}$, $-SR^{12}$, $-NR^{12}R^{13}$, -C(O)H, $-C(O)R^{12}$, $-C(O)NR^{12}R^{13}$, $-NR^{14}C(O)R^{12}$, $-C(O)OR^{12}$, $-OC(O)R^{12}$, $-OC(O)OR^{12}$,

$-S(O)R^{12}$, $-S(O)_2R^{12}$, $-S(O)NR^{12}R^{13}$, $-S(O)_2NR^{12}R^{13}$,

$-NR^{14}S(O)R^{12}$, $-NR^{14}S(O)_2R^{12}$, $-NR^{12}C(O)R^{15}$, $-NR^{12}C(O)OR^{15}$,

$-NR^{12}S(O)_2R^{15}$, $-NR^{12}C(O)NHR^{15}$;

phenyl substituted with 0-5 R^{33};

C_{3-10} carbocyclic residue substituted with 0-3 R^{33}, and

5-6 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R^{33};

R^{11} is selected from

methyl, ethyl, propyl, and phenyl substituted with 0-5 R^{23},

R^{12} is selected from

C_{1-6} alkyl substituted with 0-2 R^{12a},

C_{2-6} alkenyl substituted with 0-2 R^{12a},

C_{2-6} alkynyl substituted with 0-2 R^{12a},

C_{3-6} cycloalkyl substituted with 0-3 R^{33},

aryl substituted with 0-5 R^{33};

C_{3-10} carbocyclic residue substituted with 0-3 R^{33}, and

5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R^{33};

R^{12a}, at each occurrence, is independently selected from

H, halo, -OH, -CN, $-NO_2$, $-CO_2H$, $-SO_2R^{45}$, $-SOR^{45}$,

$-SR^{45}$, $-NR^{46}SO_2R^{45}$, $-NR^{46}COR^{45}$, $-NR^{46}R^{47}$,

$-SO_2NR^{46}R^{47}$, $-CONR^{46}R^{47}$, $-OR^{45}$, =O,

C_{1-4} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl,

phenyl substituted with 0-5 R^{33};

C_{3-10} carbocyclic residue substituted with 0-3 R^{33}, and

5-10 membered heterocyclic ring system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R^{33};

R^{13}, at each occurrence, is independently selected from
H, C_{1-4} alkyl, C_{2-4} alkenyl, and C_{2-4} alkynyl;

alternatively, R^{12} and R^{13} join to form a 5- or 6-membered ring selected from pyrrolyl, pyrrolidinyl, imidazolyl, piperidinyl, piperizinyl, methylpiperizinyl, and morpholinyl;

alternatively, R^{12} and R^{13} when attached to N may be combined to form a 9- or 10-membered bicyclic heterocyclic ring system containing from 1-3 heteroatoms selected from the group consisting of N, O, and S; wherein said bicyclic heterocyclic ring system is selected from indolyl, indolinyl, indazolyl, benzimidazolyl, benzimidazolinyl, and benztriazolyl; wherein said bicyclic heterocyclic ring system is substituted with 0-1 R^{16};

R^{14} is H, methyl, ethyl, propyl, or butyl;

R^{15} is H, methyl, ethyl, propyl, or butyl;

R^{16}, at each occurrence, is independently selected from
H, OH, F, Cl, CN, NO_2, methyl, ethyl, methoxy, ethoxy, trifluoromethyl, and trifluoromethoxy;

R^{23}, at each occurrence, is independently selected from

H, OH, F, Cl, CF_3, SO_2R^{45}, $NR^{46}R^{47}$, CN, NO_2, methyl, ethyl, propyl, and butyl;

R^{33}, at each occurrence, is independently selected from

H, OH, halo, -CN, $-NO_2$, $-CF_3$, $-OCF_3$, $-SO_2R^{35}$, $-S(=O)R^{35}$, $-SR^{35}$, $-NR^{36}R^{37}$, $-NHC(=O)R^{35}$, $-C(=O)NR^{36}R^{37}$, -C(=O)H, $-C(=O)R^{35}$, $-C(=O)OR^{35}$, $-OC(=O)R^{35}$, $-OR^{35}$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, (C_{1-4} haloalkyl)oxy, C_{3-6} cycloalkyl, phenyl, aryl substituted with 0-2 R^{34}, C_{1-6} alkyl substituted with R^{34}, and C_{2-6} alkenyl substituted with R^{34};

R^{34}, at each occurrence, is independently selected from

OH, C_{1-4} alkoxy, $-SO_2R^{35}$, $-NR^{36}R^{37}$, $NR^{36}R^{37}C(=O)-$, and (C_{1-4} alkyl)CO_2-;

R^{35}, at each occurrence, is independently selected from

C_{1-4} alkyl, C_{1-4} haloalkyl, C_{3-6} cycloalkyl, (C_{3-6} cycloalkyl)methyl-, and (C_{3-6} cycloalkyl)ethyl-;

R^{36}, at each occurrence, is independently selected from H and C_{1-4} alkyl;

R^{37}, at each occurrence, is independently selected from H, C_{1-4} alkyl, $-C(=O)NH(C_{1-4}$ alkyl), $-SO_2(C_{1-4}$ alkyl), $-C(=O)O(C_{1-4}$ alkyl), $-C(=O)(C_{1-4}$ alkyl), and -C(=O)H;

R^{45} is C_{1-4} alkyl;

R^{46}, at each occurrence, is independently selected from H and C_{1-4} alkyl;

R^{47}, at each occurrence, is independently selected from H, C_{1-4} alkyl, -C(=O)NH(C_{1-4} alkyl), -SO_2(C_{1-4} alkyl), -C(=O)O(C_{1-4} alkyl), -C(=O)(C_{1-4} alkyl), and -C(=O)H;

m is 1 or 2.

4. A compound of Claim 3 of Formula (Ib):



(Ib)

or a stereoisomer or a pharmaceutically acceptable salt form thereof, wherein:

R^1 is selected from H, methyl, and ethyl;

R^5 is H, methyl, or ethyl;

R^6 is selected from -F, -Cl, -CF_3, -OCF_3, -CF_2CF_3, -OCF_2CF_3, -OCF_2H, -OCF_2CH_3, -CN, -NO_2, -OCH_3, -OCH_2CH_3, -SCH_3, -SCH_2CH_3, -S(=O)CH_3, -$S(=O)_2CH_3$, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and s-butyl;

R^7 is H, F, or Cl;

R^8 is selected from

$-OR^{12}$, $-SR^{12}$, $-NR^{12}R^{13}$, $-C(O)R^{12}$, $-S(O)R^{12}$, $-S(O)_2R^{12}$,

C_{1-6} alkyl substituted with 0-2 R^{8a},

C_{3-6} cycloalkyl substituted with 0-2 R^{8a}, and

C_{3-10} carbocyclic residue substituted with 0-3 R^{33};

R^{8a}, at each occurrence, is independently selected from

H, F, Cl, Br, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, -OH, methoxy, ethoxy, n-propoxy, i-propoxy, $-CF_3$, $-OCF_3$, -CN, $-NO_2$, $-CF_2CF_3$,$-SCH_3$, $-SCH_2CH_3$, $-SO_2CH_3$, $-NH_2$, $-CH_2NH(CH_3)$, $-CH_2N(CH_3)_2$, $-NH(CH_3)$, $-N(CH_3)_2$, $-CO(CH_3)$, $-CO(OCH_3)$, $-NHCO(CH_3)$, $-CONH_2$, -C(=O)H, $-CH(OH)CH_3$, $-CH_2OH$, $-CH_2CH_2OH$, $-CH_2OCH_3$, $-CH_2CH_2OCH_3$, $-CH_2OCH_2CH_3$,.

phenyl substituted with 0-5 R^{33}, and pyridyl substituted with 0-5 R^{33}

R^9 is H;

R^{12} is selected from

C_{1-6} alkyl substituted with 0-2 R^{12a},

cyclopropyl substituted with 0-2 R^{33},

cyclobutyl substituted with 0-2 R^{33},

cyclopentyl substituted with 0-2 R^{33},

cyclohexyl substituted with 0-2 R^{33},

bicyclo[3.1.1]heptane substituted with 0-2 R^{33},

bicyclo[2.2.1]heptane substituted with 0-2 R^{33},

phenyl substituted with 0-3 R^{33}; and

pyridyl substituted with 0-3 R^{33};

R^{12a}, at each occurrence, is independently selected from

H, F, Cl, -OH, methyl, ethyl,
cyclopropyl substituted with 0-2 R^{33},
cyclobutyl substituted with 0-2 R^{33},
cyclopentyl substituted with 0-2 R^{33},
cyclohexyl substituted with 0-2 R^{33},
bicyclo[3.1.1]heptane substituted with 0-2 R^{33},
bicyclo[2.2.1]heptane substituted with 0-2 R^{33}, and
phenyl substituted with 0-3 R^{33};

R^{13} is H, methyl, or ethyl;

R^{33}, at each occurrence, is independently selected from
H, F, Cl, Br, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, -OH, methoxy, ethoxy, n-propoxy, i-propoxy, $-SCH_3$, $-SCH_2CH_3$, $-SO_2CH_3$, $-CF_3$, $-OCF_3$, CF_2CF_3, -CN, $-NO_2$, $-NH_2$, $-CH_2NH(CH_3)$, $-CH_2N(CH_3)_2$, $-NH(CH_3)$, $-N(CH_3)_2$, $-CO(CH_3)$, $-CO(OCH_3)$, $-NHCO(CH_3)$, $-CONH_2$, -C(=O)H, $-CH(OH)CH_3$, $-CH_2OH$, $-CH_2CH_2OH$, $-CH_2OCH_3$, $-CH_2CH_2OCH_3$, and $-CH_2OCH_2CH_3$.

5. A compound of Claim 4 of Formula (Ib):



(Ib)

or a stereoisomer or a pharmaceutically acceptable salt form thereof, wherein:

R^1 is H or methyl;

R^5 is H or methyl;

R^6 is selected from

-F, -Cl, -CF_3, -CF_2CF_3, -OCF_3, -OCF_2CF_3, -OCF_2H, -OCF_2CH_3,-CN,

-OCH_3, -SCH_3, -S(=O)CH_3, -S(=O)$_2CH_3$, or methyl;

R^7 is H, F, or Cl;

R^8 is selected from

-OR^{12}, -SR^{12}, -$NR^{12}R^{13}$,

C_{1-6} alkyl substituted with 0-2 R^{8a}, and

C_{3-6} cycloalkyl substituted with 0-2 R^{8a},

R^{8a}, at each occurrence, is independently selected from

H, F, Cl, Br, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl,

t-butyl, -OH, methoxy, ethoxy, n-propoxy, i-propoxy, -CF_3, -OCF_3,

-CN, -CF_2CF_3,-SCH_3, -SCH_2CH_3, -$CH_2NH(CH_3)$, -$CH_2N(CH_3)_2$,

-$NH(CH_3)$, -$N(CH_3)_2$, -$CO(CH_3)$, -$CO(OCH_3)$, -$NHCO(CH_3)$, -$CONH_2$,

-$CH(OH)CH_3$, -CH_2OH, -CH_2CH_2OH, -CH_2OCH_3, -$CH_2CH_2OCH_3$,

-$CH_2OCH_2CH_3$, phenyl substituted with 0-5 R^{33}, and

pyridyl substituted with 0-5 R^{33}

R^9 is H;

R^{12} is selected from

methyl, ethyl, propyl, butyl, pentyl, hexyl,

cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,

bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane,

methyl substituted with R^{12a};

ethyl substituted with R^{12a};

propyl substituted with R^{12a};

phenyl substituted with 0-2 R^{33}; and

pyridyl substituted with 0-2 R^{33};

R^{12a} is selected from

cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, and

phenyl substituted with 0-2 R^{33};

R^{13} is H, methyl, or ethyl;

R^{33}, at each occurrence, is independently selected from

H, F, Cl, Br, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl,
t-butyl, -OH, methoxy, ethoxy, n-propoxy, i-propoxy, $-SCH_3$, $-SCH_2CH_3$,
$-SO_2CH_3$, $-CF_3$, $-OCF_3$, -CN, $-NO_2$, $-NH_2$, $-CH_2NH(CH_3)$,
$-CH_2N(CH_3)_2$, $-NH(CH_3)$, $-N(CH_3)_2$, $-CO(CH_3)$, $-CO(OCH_3)$,
$-NHCO(CH_3)$, $-CONH_2$, -C(=O)H, $-CH(OH)CH_3$, $-CH_2OH$, $-CH_2CH_2OH$,
$-CH_2OCH_3$, $-CH_2CH_2OCH_3$, and $-CH_2OCH_2CH_3$.

6. A compound of Claim 1 of Formula (Ic):



(Ic)

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

8. A method for treating a human suffering from a disorder associated with $5HT_{2C}$ receptor modulation comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

9. A method of Claim 8 for treating a human suffering from a disorder associated with $5HT_{2C}$ receptor modulation wherein the compound is a $5HT_{2C}$ agonist.

10. A method for treating obesity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.